LU88831I2 - Lispro et ses sels pharmaceutiquement acceptables - Google Patents

Lispro et ses sels pharmaceutiquement acceptables

Info

Publication number
LU88831I2
LU88831I2 LU88831C LU88831C LU88831I2 LU 88831 I2 LU88831 I2 LU 88831I2 LU 88831 C LU88831 C LU 88831C LU 88831 C LU88831 C LU 88831C LU 88831 I2 LU88831 I2 LU 88831I2
Authority
LU
Luxembourg
Prior art keywords
absent
lys
threonine
arg
aspartic acid
Prior art date
Application number
LU88831C
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88831(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of LU88831I2 publication Critical patent/LU88831I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C07K14/622—Insulins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU88831C 1989-02-09 1990-02-06 Lispro et ses sels pharmaceutiquement acceptables LU88831I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30835289A 1989-02-09 1989-02-09
US38820189A 1989-08-04 1989-08-04

Publications (1)

Publication Number Publication Date
LU88831I2 true LU88831I2 (fr) 1997-01-10

Family

ID=26976211

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88830C LU88830I2 (fr) 1989-02-09 1990-02-06 Lispro et ses sels pharmaceutiquement acceptables
LU88831C LU88831I2 (fr) 1989-02-09 1990-02-06 Lispro et ses sels pharmaceutiquement acceptables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU88830C LU88830I2 (fr) 1989-02-09 1990-02-06 Lispro et ses sels pharmaceutiquement acceptables

Country Status (24)

Country Link
EP (2) EP0678522B1 (fr)
JP (1) JPH0822878B2 (fr)
KR (1) KR0169727B1 (fr)
CN (2) CN1034080C (fr)
AT (1) ATE133961T1 (fr)
AU (1) AU630912B2 (fr)
BG (1) BG60769B2 (fr)
CA (1) CA2009579C (fr)
CY (1) CY1911A (fr)
DE (3) DE69033889T2 (fr)
DK (2) DK0678522T3 (fr)
ES (2) ES2170122T3 (fr)
FI (1) FI95915C (fr)
GR (1) GR3019501T3 (fr)
HK (1) HK60296A (fr)
HU (2) HU212679B (fr)
IE (1) IE73251B1 (fr)
IL (1) IL93282A (fr)
LU (2) LU88830I2 (fr)
NL (1) NL960026I2 (fr)
NO (2) NO179587C (fr)
NZ (1) NZ232375A (fr)
PT (1) PT93057B (fr)
RU (1) RU2109749C1 (fr)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641631B2 (en) * 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
IL102240A0 (en) * 1991-06-21 1993-01-14 Lilly Co Eli Insulin analogs
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP1607086A1 (fr) * 1993-01-29 2005-12-21 Aradigm Corporation Procédé d'utilisation d'insuline monomère en tant que moyen servant à améliorer la réproductibilité de l'insuline inhalée
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1996034882A1 (fr) * 1995-05-05 1996-11-07 Eli Lilly And Company Insuline monocatenaire a bioactivite elevee
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
HU228094B1 (en) * 1996-06-20 2012-10-29 Novo Nordisk As Insulin preparations containing nacl
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
CA2306905A1 (fr) 1997-10-24 1999-05-06 Eli Lilly And Company Analogues d'insuline acylee par un acide gras
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
DE19805822B4 (de) * 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
AU2003218635A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
CN101955527B (zh) 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
ES2660320T3 (es) 2003-11-20 2018-03-21 Novo Nordisk A/S Formulaciones peptídicas que contienen propilenglicol que son óptimas para la producción y para el uso en dispositivos de inyección
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
EP1773878B1 (fr) 2004-07-19 2015-03-04 Biocon Limited Conjugués insuline-oligomère, préparations et utilisations de ceux-ci
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
JPWO2006093222A1 (ja) * 2005-03-02 2008-08-07 味の素株式会社 インスリンの多量体形成阻害剤
JP5366546B2 (ja) 2005-08-16 2013-12-11 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
CA2621344C (fr) 2005-09-14 2014-12-16 Sanofi-Aventis Deutschland Gmbh Clivage de precurseurs d'insulines par un variant de la trypsine
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
ATE557037T1 (de) 2006-02-27 2012-05-15 Novo Nordisk As Insulin derivate
ES2397659T3 (es) 2006-03-15 2013-03-08 Novo Nordisk A/S Mezclas de amilina e insulina
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
ES2553154T3 (es) 2006-05-09 2015-12-04 Novo Nordisk A/S Derivado de la insulina
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145728A1 (fr) 2007-06-01 2008-12-04 Novo Nordisk A/S Préconcentrés spontanément dispersibles comprenant un médicament peptidique dans un excipient solide ou semi-solide
WO2008145732A1 (fr) 2007-06-01 2008-12-04 Novo Nordisk A/S Compositions pharmaceutiques non aqueuses stables
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
US20120232002A1 (en) 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
SI2451437T1 (sl) 2009-07-06 2017-03-31 Sanofi-Aventis Deutschlad Gmbh Vodni pripravki, ki vsebujejo metionin
EP2451472A1 (fr) 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Préparations d'insuline stables à la chaleur et aux agitations
EP2459228B1 (fr) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Promédicament comprenant un conjugué insuline-lieur
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2612468T3 (es) 2010-05-10 2017-05-17 Novo Nordisk A/S Procedimiento para la preparación de complejos de insulina-zinc
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
PL2632478T3 (pl) 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CN102199206B (zh) * 2011-03-17 2013-03-20 甘李药业股份有限公司 快速起效且在酸性条件下稳定的胰岛素类似物及其制剂
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112014026442A8 (pt) 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
WO2014102623A1 (fr) 2012-12-26 2014-07-03 Wockhardt Limited Composition pharmaceutique
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
AR095986A1 (es) * 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
EP2991672A1 (fr) 2013-04-30 2016-03-09 Novo Nordisk A/S Schéma d'administration d'un nouveau type
WO2015044922A1 (fr) 2013-09-30 2015-04-02 Wockhardt Limited Composition pharmaceutique
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2015191705A1 (fr) * 2014-06-10 2015-12-17 California Institute Of Technology Insulines non canoniques et leurs utilisations
WO2016001862A1 (fr) 2014-07-04 2016-01-07 Wockhardt Limited Formulations à libération prolongée d'insulines
EP3229828B1 (fr) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
TWI774694B (zh) * 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
US20190290737A1 (en) 2016-09-29 2019-09-26 Arecor Limited Novel formulations
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2019193351A1 (fr) 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
CA3094304A1 (fr) 2018-04-04 2019-10-10 Arecor Limited Systeme de pompe a perfusion medicale pour l'administration d'un compose d'insuline
US20210038506A1 (en) 2018-04-04 2021-02-11 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20200082618A (ko) 2018-12-31 2020-07-08 주식회사 폴루스 인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
WO2021136296A1 (fr) 2019-12-30 2021-07-08 甘李药业股份有限公司 Dérivé d'insuline
MX2022008139A (es) 2019-12-30 2022-10-03 Gan & Lee Pharmaceuticals Co Ltd Compuestos de glp-1 de acción prolongada.
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK129385A (da) * 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence

Also Published As

Publication number Publication date
PT93057B (pt) 1995-12-29
EP0383472A3 (fr) 1991-09-18
DE69033889D1 (de) 2002-02-07
NO1996013I1 (no) 1996-12-09
IL93282A0 (en) 1990-11-29
HUT57795A (en) 1991-12-30
GR3019501T3 (en) 1996-07-31
LU88830I2 (fr) 1997-01-06
DK0383472T3 (da) 1996-05-06
NO900615D0 (no) 1990-02-08
NO179587C (no) 1996-11-06
EP0383472A2 (fr) 1990-08-22
DE69033889T2 (de) 2002-08-22
NZ232375A (en) 1992-04-28
CN1103602C (zh) 2003-03-26
DE69025210D1 (de) 1996-03-21
IE73251B1 (en) 1997-05-21
FI95915C (fi) 1996-04-10
ATE133961T1 (de) 1996-02-15
HU211276A9 (en) 1995-11-28
EP0678522A1 (fr) 1995-10-25
NL960026I2 (nl) 1997-05-01
CN1034080C (zh) 1997-02-19
KR900012627A (ko) 1990-09-01
JPH02264798A (ja) 1990-10-29
EP0678522B1 (fr) 2002-01-02
CN1044820A (zh) 1990-08-22
CY1911A (en) 1990-02-06
FI95915B (fi) 1995-12-29
NO900615L (no) 1990-08-10
CN1148984A (zh) 1997-05-07
DE19675034I2 (de) 2006-11-16
ES2083424T3 (es) 1996-04-16
DE69025210T2 (de) 1996-06-13
JPH0822878B2 (ja) 1996-03-06
AU4922690A (en) 1990-08-16
BG60769B2 (bg) 1996-02-29
CA2009579A1 (fr) 1990-08-09
NO179587B (no) 1996-07-29
HU900726D0 (en) 1990-04-28
ES2170122T3 (es) 2002-08-01
RU2109749C1 (ru) 1998-04-27
EP0383472B1 (fr) 1996-02-07
IE900440L (en) 1990-08-09
DK0678522T3 (da) 2002-03-11
NL960026I1 (nl) 1997-01-06
CA2009579C (fr) 2000-04-11
AU630912B2 (en) 1992-11-12
PT93057A (pt) 1990-08-31
IL93282A (en) 1995-08-31
KR0169727B1 (ko) 1999-01-15
FI900600A0 (fi) 1990-02-07
HK60296A (en) 1996-04-12
HU212679B (en) 1996-09-30

Similar Documents

Publication Publication Date Title
LU88831I2 (fr) Lispro et ses sels pharmaceutiquement acceptables
ES2526707T3 (es) Purificación y estabilización de péptidos y proteínas en agentes farmacéuticos
HU906177D0 (en) Process for the production of peptide derivatives and medical and diagnostical preparations containing such derivatives
EP0512042A4 (en) Glp-1 analogs useful for diabetes treatment
AU7591687A (en) Novel peptides and injectable solutions having prolonged insulin action
WO2000012542A3 (fr) Peptides bioactifs
ATE95195T1 (de) Mikroproteine, verfahren zur herstellung derselben und anwendung dieser mikroproteine als arzneimittel.
FI893833A0 (fi) Rekombinant aktivator foer naturliga doedarceller.
KR910002899A (ko) 혈조절 펩타이드
FI925972A0 (fi) Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning
ATE138936T1 (de) Neue peptidderivate, verfahren zu deren herstellung und deren anwendung als heilmittel
ATE233105T1 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
ES2135389T3 (es) Antagonistas de endotelina.
DK411686A (da) Peptider